BRD9 and melanoma: Targeting the druggable SWI/SNF bromodomains (BRD7, BRD9, SMARCA4, SMARCA2), using the BET inhibitors as long as the HDAC inhibitors and identification of synthetic lethal interactions involved in melanoma such as SMARCA4 and ARID2 presents an additional possibility for novel strategies targeting the SWI/SNF subunits toward precise medicine of melanoma.